

REMARKS

With the cancellation of claims 1-3, claims 4-8 are pending.

Descriptive support for the amendment to claim 4 can be found in claim 1 as filed.


Applicants elect claims 6-9 of Group III with traverse because claims 4-5 have unity of invention with claims 6-9 since these claims share the special technical feature of preventing or treating cerebral infarct in human beings with L-butylphthalide of formula (I). Applicants request that claims 4-5 be rejoined with the elected claims 6-9 in the examination.

The Examiner is invited to contact the undersigned at 202-220-4200 to discuss any matter in connection with this application.

In the event that the filing of this paper is deemed not timely, applicants petition for an appropriate extension of time. The Office is hereby authorized to charge any fees in relation to this paper under 37 C.F.R. 1.16 and 1.17 to the Kenyon & Kenyon Deposit Account No. 11-0600.

Respectfully submitted,

Dated: January 16, 2009



King L. Wong
(Reg. No. 37,500)

KENYON & KENYON LLP
1500 K Street, N.W., Suite 700
Washington, DC 20005-1257
Tel: (202) 220-4200
Fax: (202) 220-4201